title: Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications.
abstract: OBJECTIVE
  To assess compliance to guidelines in the management of patients with atrial fibrillation.
  
  
  RESULTS
  A total of 728 questionnaires were mailed to physicians with the intention of studying 'theoretical' compliance to practice guidelines. A retrospective evaluation of 200 records from consecutive patients hospitalized with atrial fibrillation was performed in order to verify 'actual' compliance to guidelines. The response rate to the questionnaires was 68%. More than 94% of the physicians stated that patients with risk factors for thromboembolic complications and chronic atrial fibrillation should receive long-term warfarin treatment. Of evaluated records, 108 patients were in chronic atrial fibrillation with at least one risk factor for stroke, and with no known contraindication to warfarin. In this group, only 40% received warfarin. Moreover, several other discrepancies were detected as regards the use of antiarrhythmic therapy.
  
  
  CONCLUSIONS
  This study reveals a clear discrepancy between recommendations in guidelines and actual practice in patients with atrial fibrillation. The most important finding was a significant under use of thromboembolic prophylaxis in patients at high risk for such events. Implementation and the study of adherence to management guidelines on atrial fibrillation need to be carefully reviewed by surveys of actual clinical practice in order to establish reasonable therapeutic quality.
authors.affiliation: Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: V
authors.initials: V
authors.lastname: Frykman
authors.forename: B
authors.initials: B
authors.lastname: Beerman
authors.forename: L
authors.initials: L
authors.lastname: Rydén
authors.forename: M
authors.initials: M
authors.lastname: Rosenqvist
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000191:economics / Q000592:standards / Q000627:therapeutic use; D001241:Aspirin / Q000191:economics / Q000592:standards / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000628:therapy*; D017147:Defibrillators, Implantable / Q000592:standards; D004452:Echocardiography; D004562:Electrocardiography; D005252:Fees, Pharmaceutical; D017408:Guidelines as Topic; D006801:Humans; D008875:Middle Aged; D010349:Patient Compliance / Q000523:psychology; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D013995:Time; D013997:Time Factors; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology; D014481:United States / Q000453:epidemiology; D014859:Warfarin / Q000191:economics / Q000592:standards / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D001241:Aspirin